logo-loader
viewCynata Therapeutics Ltd

Cynata Therapeutics announces trial in critical COVID-19 patients using their technology

Cynata Therapeutics (ASX: CYP) COO Kilian Kelly joined Steve Darling from Proactive Vancouver with news the unique stem cell biotech company is beginning a trial in patients suffering from the effects of the coronavirus.

Kelly telling Proactive how their technology works and why this technology is quite different from other stem cell companies. Kelly also talked about some of the pre and current clinical results.

Quick facts: Cynata Therapeutics Ltd

Price: 0.605 AUD

ASX:CYP
Market: ASX
Market Cap: $70.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cynata Therapeutics Ltd named herein, including the promotion by the Company of Cynata Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

[email protected] Capital CEO discusses new Head of Enterprise Risk Management hire

[email protected] Capital PLC's (LON:SYME) Alessandro Zamboni speaks to Proactive following the announcement they've appointed Stuart Nelson as Head of Enterprise Risk Management (ERM). Zamboni says Nelson is a highly experienced credit analyst with experience assessing risk across multiple product...

1 hour, 26 minutes ago

2 min read